Background Atrial fibrillation (AF) is caused by different mechanisms but current treatment
strategies do not target these mechanisms. Stratified therapy based on mechanistic drivers …

Objective Atrial fibrillation (AF) often progresses from paroxysmal AF (PAF) to more
permanent forms. To improve personalised medicine, we aim to develop a new AF …

Aims Atrial fibrillation (AF) is a progressive disease, but identifying patients at risk for AF
progression is challenging. We aimed to identify factors associated with AF progression …

Background Atrial fibrillation (AF) is the arrhythmia most commonly diagnosed in clinical
practice. It is associated with significant morbidity and mortality. Prevalence of AF and …

Atrial fibrillation (AF) is the most common sustained arrhythmia all over the world and is
burdened by high morbidity and mortality as well as a significantly negative impact on …

Atrial fibrillation (AF) has heterogeneous patterns of presentation concerning symptoms,
duration of episodes, AF burden, and the tendency to progress towards the terminal step of …

The management of atrial fibrillation (AF) has seen marked changes in past years, with the
introduction of new oral anticoagulants, new antiarrhythmic drugs, and the emergence of …

Aims The risk of developing atrial fibrillation (AF) and its complications continues to
increase, despite good progress in preventing AF-related strokes. Methods and results This …

Background More sustained forms of atrial fibrillation (AF) are less amenable to treatment
and associated with worse outcomes, but the incidence and predictors of AF progression are …

Atrial fibrillation (AF) is the most common cardiac arrhythmia; the lifetime risk is 1 in 4 for
persons over the age of 40 years in the United States. 1 AF is associated with an increased …